Celltrion's biosimilar Stekima has captured 16.2% market share in the US ustekinumab category as of July 2026. Stekima is a copycat drug version of Janssen's Stelara, used to treat psoriasis and Crohn's disease.
Celltrion's US strategy includes direct doctor engagement and insurance plan coverage. This has driven fast growth since launch. The copycat drug market is expanding as patents on blockbuster medications run out and expire.
Celltrion reported FY2025 net income of ₩185.2 billion. The company operates manufacturing facilities in South Korea and Ireland supplying hospitals and specialty pharmacies worldwide.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 068270Celltrion, Inc. | ₩188,100 +0.5% |